PVLA
Palvella Therapeutics, Inc.
$151.97
+2.29 (+1.53%)
At close · Jul 15
Market Cap
$2.18B
Shares
14,342,844
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
No Compensation Data
No Summary Compensation Table has been imported from this company's proxy statements yet.
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Matthew Pauls | Class I director | Appointed | 2026-06-30 |